Morgan Stanley Cuts Trevi Therapeutics (NASDAQ:TRVI) Price Target to $18.00

Trevi Therapeutics (NASDAQ:TRVI) had its price target reduced by Morgan Stanley from $19.00 to $18.00 in a research note released on Wednesday,Benzinga reports. Morgan Stanley currently has an overweight rating on the stock.

Several other equities analysts have also weighed in on the stock. D. Boral Capital restated a “buy” rating and set a $19.00 price objective on shares of Trevi Therapeutics in a research report on Wednesday. Needham & Company LLC boosted their target price on shares of Trevi Therapeutics from $22.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday. Oppenheimer reissued an “outperform” rating on shares of Trevi Therapeutics in a research note on Monday, March 9th. Leerink Partners raised their target price on shares of Trevi Therapeutics from $13.00 to $16.00 and gave the stock an “outperform” rating in a report on Wednesday, November 19th. Finally, HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of Trevi Therapeutics in a research report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Trevi Therapeutics presently has a consensus rating of “Buy” and an average price target of $21.60.

Trevi Therapeutics Stock Performance

TRVI opened at $10.61 on Wednesday. The company has a market capitalization of $1.36 billion, a PE ratio of -33.16 and a beta of 0.94. The stock’s fifty day moving average is $11.13 and its 200-day moving average is $10.95. Trevi Therapeutics has a one year low of $4.85 and a one year high of $14.39.

Trevi Therapeutics (NASDAQ:TRVI) last announced its earnings results on Tuesday, March 17th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.04. On average, equities research analysts forecast that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Institutional Investors Weigh In On Trevi Therapeutics

Hedge funds have recently made changes to their positions in the company. Rubric Capital Management LP boosted its stake in Trevi Therapeutics by 88.0% in the 2nd quarter. Rubric Capital Management LP now owns 8,531,860 shares of the company’s stock worth $46,669,000 after purchasing an additional 3,993,325 shares during the period. Vanguard Group Inc. raised its stake in Trevi Therapeutics by 10.4% during the 4th quarter. Vanguard Group Inc. now owns 6,434,655 shares of the company’s stock valued at $80,562,000 after purchasing an additional 607,669 shares during the period. Viking Global Investors LP raised its stake in Trevi Therapeutics by 232.4% during the 3rd quarter. Viking Global Investors LP now owns 5,128,875 shares of the company’s stock valued at $46,929,000 after purchasing an additional 3,585,875 shares during the period. Vivo Capital LLC lifted its holdings in shares of Trevi Therapeutics by 13.5% in the third quarter. Vivo Capital LLC now owns 5,094,668 shares of the company’s stock valued at $46,616,000 after purchasing an additional 606,765 shares in the last quarter. Finally, Marshall Wace LLP lifted its holdings in shares of Trevi Therapeutics by 95.4% in the third quarter. Marshall Wace LLP now owns 4,841,751 shares of the company’s stock valued at $44,302,000 after purchasing an additional 2,363,835 shares in the last quarter. Hedge funds and other institutional investors own 95.76% of the company’s stock.

Trending Headlines about Trevi Therapeutics

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: Trevi beat Q4 2025 EPS expectations (reported -$0.06 vs. about -$0.096), providing near-term fundamental support and likely driving early buying interest after the print. Q4 2025 earnings transcript
• Positive Sentiment: Needham raised its price target to $24, signaling continued analyst conviction and a sizable implied upside from current levels. Needham raises PT to $24
• Positive Sentiment: D. Boral Capital reaffirmed a Buy rating, adding to the roster of buy-side endorsements that may support demand in the shares. D. Boral Capital reaffirms Buy
• Positive Sentiment: JonesTrading trimmed its price target slightly (from $25 to $24) but kept a Buy rating — the change is modest and leaves a large upside implied by street targets. JonesTrading PT update
• Neutral Sentiment: Full earnings-call transcript and coverage are available for investors reviewing management commentary and execution details; useful for gauging guidance and pipeline progress but not new news by itself. Earnings transcript
• Neutral Sentiment: Analyst write-ups (e.g., Globe and Mail summary) provide context and viewpoints but do not change fundamentals immediately. Analyst insights
• Negative Sentiment: HC Wainwright cut multi-year EPS forecasts across FY2026–FY2029 (notably downgrading several yearly EPS projections) while maintaining a Buy rating and a $21 target — the lower earnings trajectory may temper enthusiasm around near-term profitability and valuation. HC Wainwright estimate revisions
• Negative Sentiment: Morgan Stanley signaled lower expectations for TRVI, adding downward pressure from a major institutional voice and contributing to intraday weakness. Morgan Stanley lowers expectations

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.